Trial · NCT04399980

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04399980, Phase 2, Completed, The Cleveland Clinic; results first posted 2021-05-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation. Trials, record NCT04399980. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04399980

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
NCT number: NCT04399980
Status: Completed
Phases: Phase 2
Enrollment: 40 participants, actual
Lead sponsor: The Cleveland Clinic
Conditions: COVID 19, SARS-CoV 2, Pneumonia
Interventions: Mavrilimumab, Placebos
First posted: 2020-05-22
Last updated: 2021-05-13
Results first posted: 2021-05-13

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Subjects Alive and Off of Oxygen at Day 14	Day 14	Number and percentage of subjects alive and off of oxygen at day 14
Secondary	Number of Subjects Alive and Without Respiratory Failure at Day 28	Day 28	Number and percentage of subjects that are alive and without respiratory failure at Day 28
Secondary	Mortality at Day 28	Day 28	Number and percentage of patients that expired by Day 28

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Subjects Alive and Off of Oxygen at Day 14	Day 14	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Subjects Alive and Without Respiratory Failure at Day 28	Day 28	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Mortality at Day 28	Day 28	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Subjects Alive and Off of Oxygen at Day 14	Intervention	12	Participants
Subjects Alive and Off of Oxygen at Day 14	Control	9	Participants
Number of Subjects Alive and Without Respiratory Failure at Day 28	Intervention	20	Participants
Number of Subjects Alive and Without Respiratory Failure at Day 28	Control	15	Participants
Mortality at Day 28	Intervention	1	Participants
Mortality at Day 28	Control	3	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Intervention	21
Overall Study	STARTED	Control	19
Overall Study	COMPLETED	Intervention	21
Overall Study	COMPLETED	Control	19
Overall Study	NOT COMPLETED	Intervention	0
Overall Study	NOT COMPLETED	Control	0

Source ClinicalTrials.gov

Adverse events48

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Acute Kidney Injury	Renal and urinary disorders	Intervention	4	21	4
other	Acute Kidney Injury	Renal and urinary disorders	Control	3	19	3
other	anemia	Blood and lymphatic system disorders	Intervention	2	21	2
other	anemia	Blood and lymphatic system disorders	Control	2	19	2
other	Arrhythmia	Cardiac disorders	Intervention	0	21	0
other	Arrhythmia	Cardiac disorders	Control	2	19	2
other	Headache	General disorders	Intervention	0	21	0
other	Headache	General disorders	Control	1	19	1
other	Liver Dysfunction	Hepatobiliary disorders	Intervention	3	21	3
other	Liver Dysfunction	Hepatobiliary disorders	Control	0	19	0

1 to 10 of 48Source ClinicalTrials.gov

See all 48 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Intervention	1	21
Total, all-cause mortality	Control	4	19
Total, other adverse events	Intervention	12	21
Total, other adverse events	Control	8	19
Total, serious adverse events	Intervention	5	21
Total, serious adverse events	Control	4	19

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33754144	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons5

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Intervention vs Control: Mortality at Day 28	Trial comparisons
Intervention vs Control: Number of Subjects Alive and Without Respiratory Failure at Day 28	Trial comparisons
Intervention vs Control: Subjects Alive and Off of Oxygen at Day 14	Trial comparisons
Intervention vs Control: deaths from any cause	Trial comparisons
Intervention vs Control: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04399980

GET https://conductscience.org/api/trials/v1/NCT04399980/events?page=2

API reference For AI assistants